ESR1 and neoplasm: Although ER/HER2-positive and ER/HER2-negative cells differ in their extent and timing of glucose dependency, the aforementioned studies may suggest that tumour metabolic characteristics could be considered either biomarkers to monitor the therapeutic responses or targets to overcome therapeutic resistance.